## 1 Prediabetes as a risk factor for all-cause and cause-specific mortality: a

## 2 prospective analysis of 115,919 adults without diabetes in Mexico City

Carlos A. Fermín-Martínez<sup>1,2\*</sup>, Omar Yaxmehen Bello-Chavolla<sup>1\*</sup>, César Daniel Paz-3 Cabrera<sup>1,3</sup>, Daniel Ramírez-García<sup>1,4</sup>, Jerónimo Perezalonso-Espinosa<sup>1,2</sup>, 4 Luisa Fernández-Chirino<sup>1,5</sup>, Arsenio Vargas-Vázquez<sup>2</sup>, Juan Pablo Díaz-Sánchez<sup>1,2</sup>, Padme 5 Nailea Méndez-Labra<sup>1,2</sup>, Alejandra Núñez-Luna<sup>1,4</sup>, Martín Roberto Basile-Alvarez<sup>1,4</sup>, 6 Paulina Sánchez-Castro<sup>1,4</sup>, Fiona Bragg<sup>5,6</sup>, Louisa Gnatiuc Friedrichs<sup>5,6</sup>, Diego Aguilar-7 Ramírez,<sup>5</sup> Jonathan R. Emberson,<sup>5,6</sup> Jaime Berumen-Campos<sup>4</sup>, Pablo Kuri-Morales<sup>4,7</sup>, 8 Roberto Tapia-Conver<sup>4</sup>, Jesus Alegre-Díaz<sup>8,+</sup>, Jacqueline A. Seiglie<sup>9,10+</sup>, Neftali Eduardo 9 Antonio-Villa<sup>11,+</sup> 10

## \*Equal first author, \*Equal last author

11 12

<sup>1</sup>Research Division, Instituto Nacional de Geriatría, Mexico City, Mexico. <sup>2</sup>MD/PhD 13 (PECEM) Program, Facultad de Medicina, Universidad Nacional Autónoma de México, 14 Mexico City, Mexico. <sup>3</sup>Especialidad en Medicina Preventiva, Instituto Nacional de Salud 15 Pública, Mexico City, Mexico. <sup>4</sup>Facultad de Medicina, Universidad Nacional Autónoma de 16 México, Mexico City, Mexico. <sup>5</sup>Clinical Trial Service Unit and Epidemiological Studies Unit, 17 Nuffield Department of Population Health, University of Oxford, Oxford, UK, <sup>6</sup>MRC 18 Population Health Research Unit, Nuffield Department of Population Health, University of 19 Oxford, Oxford, UK. <sup>7</sup>Instituto Tecnológico y de Estudios Superiores de Monterrey, 20 Monterrey, Mexico. <sup>8</sup>Experimental Research Unit, Faculty of Medicine, National 21 Autonomous University of Mexico, Mexico City, Mexico. <sup>9</sup>Diabetes Unit, Massachusetts 22 General Hospital, Harvard Medical School, Boston, Massachusetts, USA. <sup>10</sup>Department of 23 Medicine, Harvard Medical School, Boston, Massachusetts, USA. <sup>11</sup>Department of 24 25 Endocrinology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.

26

## 27 Correspondence:

Omar Yaxmehen Bello-Chavolla. Division of Research. Instituto Nacional de Geriatría.
Anillo Perif. 2767, San Jerónimo Lídice, La Magdalena Contreras, 10200, Mexico City,
Mexico. Phone: +52 (55) 5548486885. E-mail: <u>oybello@inger.gob.mx</u>.

Neftali Eduardo Antonio-Villa. Department of Endocrinology, Instituto Nacional de 31 Cardiología Ignacio Chávez. Juan Badiano 1, Belisario Domínguez Secc 16, Tlalpan, 32 14080 33 Mexico City, Mexico. Phone +52 (55) 5527236523. Email: 34 neftalivilla@comunidad.unam.mx

35

36 2,803 text words; 36 references; 3 figures, 2 tables.

## 37 ABSTRACT (350 WORDS)

BACKGROUND: Prediabetes has been associated with increased all-cause and
 cardiovascular mortality. However, no large-scale studies have been conducted in Mexico
 or Latin America examining these associations.

41 **METHODS**: We analyzed data from 115,919 adults without diabetes (diagnosed or 42 undiagnosed) aged 35-84 years who participated in the Mexico City Prospective Study 43 between 1998 and 2004. Participants were followed until January 1<sup>st</sup>, 2021 for cause-44 specific mortality. We defined prediabetes according to the American Diabetes Association 45 (ADA, HbA<sub>1c</sub> 5.7% to 6.4%) and the International Expert Committee (IEC, HbA<sub>1c</sub> 6.0-6.4%) 46 definitions. Cox regression adjusted for confounders was used to estimate all-cause and 47 cause-specific mortality rate ratios (RR) at ages 35-74 years associated with prediabetes.

48 FINDINGS: During 2,085,392 person-years of follow-up (median in survivors 19 years), there were 6,810 deaths at ages 35-74, including 1,742 from cardiovascular disease, 892 49 50 from renal disease and 108 from acute diabetic crises. Of 110,405 participants aged 35-74 years at recruitment, 28,852 (26%) had ADA-defined prediabetes and 7,203 (7%) had IEC-51 52 defined prediabetes. Compared with those without prediabetes, individuals with prediabetes had higher risk of all-cause mortality at ages 35-74 years (RR 1.13, 95% CI 53 54 1.07-1.19 for ADA-defined prediabetes and RR 1.28, 1.18-1.39 for IEC-defined prediabetes), as well as increased risk of cardiovascular mortality (RR 1.22 [1.10-1.35] and 55 56 1.42 [1.22-1.65], respectively), renal mortality (RR 1.35 [1.08-1.68] and 1.69 [1.24-2.31], respectively), and death from an acute diabetic crisis (RR 2.63 [1.76-3.94] and 3.43 [2.09-57 5.62], respectively). RRs were larger at younger than at older ages, and similar for men 58 compared to women. The absolute excess risk associated with ADA and IEC-defined 59 prediabetes at ages 35-74 accounted for6% and 3% of cardiovascular deaths respectively, 60 10% and 5% of renal deaths respectively, and 31% and 14% of acute diabetic deaths 61 62 respectively.

63 INTERPRETATION: Prediabetes is a significant risk factor for all-cause, cardiovascular, 64 renal, and acute diabetic deaths in Mexican adults. Identification and timely management 65 of individuals with prediabetes for targeted risk reduction could contribute to reducing 66 premature mortality from cardiometabolic causes in this population.

FUNDING: Wellcome Trust, the Mexican Health Ministry, the National Council of Science
and Technology for Mexico, Cancer Research UK, British Heart Foundation, UK Medical
Research Council. Instituto Nacional de Geriatría (Mexico City).

70

## 71 **RESEARCH IN CONTEXT**

## 72 Evidence before this study

We conducted a literature search in PubMed to identify articles published in English before 73 February 27<sup>th</sup>, 2024 that reported on prospective studies examining the association 74 between prediabetes with all-cause or cause-specific mortality or progression to diabetes 75 76 in a Mexican or Latin American population, using the terms ("prediabetes" OR "impaired 77 fasting glucose" OR "impaired glucose tolerance") AND ("mortality" OR "death") AND ("Mexico" OR "Mexican" OR "Latin America" OR "Latin American"). There were no studies 78 examining risk associated with prediabetes definitions and mortality among adults in 79 80 Mexico. We identified one study from Peru that included 988 participants and investigated only all-cause mortality for impaired fasting glucose and HbA1c-based definitions of 81 prediabetes from ADA and IEC; this study reported increased mortality risk related to ADA-82 defined prediabetes based on HbA<sub>1c</sub> measures. Generalizability of these findings to other 83 Latin American countries and regions with distinct cardiometabolic profiles in unclear. 84

## 85 Added value of this study

Our study included 115,919 participants without diabetes from Mexico City, of whom 86 (26%) had ADA-defined prediabetes and 7,203 (7%) had IEC-defined prediabetes. We 87 found that prediabetes is associated with higher risks of all-cause and cause-specific 88 89 mortality (cardiovascular, renal, and acute diabetic causes) than among participants without prediabetes. We found RRs to be larger at younger than at older ages, and largely 90 91 similar for men compared to women. Among those without previously diagnosed diabetes, 92 we found that the excess risk associated with ADA- and IEC-defined prediabetes at ages 93 35-74 years accounted for 6% and 3% of cardiovascular deaths, 10% and 5% of renal 94 deaths, and 31% and 14% of acute diabetic deaths, respectively. .

#### 95 Implications of all the available evidence

Our results show that prediabetes is a significant risk factor for cardiovascular, kidney, and acute diabetic deaths among Mexican adults and accounts for a notable fraction of such deaths. Identification of individuals with prediabetes should be prioritized for optimized management to improve cardiometabolic outcomes in Mexican adults.

## 101 **INTRODUCTION**

Although the definition of prediabetes is the subject of continuous debate, it is well-102 103 recognized as a risk factor for development of type 2 diabetes and long-term adverse cardio-metabolic outcomes<sup>1-3</sup>. Prediabetes is an early stage indicator of glycemic 104 dysregulation, and individuals with prediabetes often present with other traits of the 105 106 metabolic syndrome (i.e. dysfunctional adipose tissue accumulation, dyslipidemia, insulin 107 resistance)<sup>4,5</sup>. Despite its pathophysiological relevance and the overwhelming increase in the incidence of metabolic syndrome in susceptible populations, routine screening for 108 109 prediabetes is disputed, in part due to a lack of consensus on how it should be defined<sup>1</sup>. 110 Growing evidence supports that beyond its well-known association with progression to 111 diabetes, prediabetes also increases the risk of cardiovascular disease and mortality<sup>3</sup>. 112 Nevertheless, data on prediabetes-associated complications beyond progression to 113 diabetes are limited, particularly in low- and middle-income countries (LMICs)<sup>6</sup>.

114 In Mexico, the prevalence of diabetes has increased at an alarming rate in recent 115 decades<sup>7</sup>. This trend can be attributed to a complex interplay of underlying genetic risk and changes in environmental factors<sup>8-10</sup>, which have led to a steady increase in central 116 obesity, impaired glucose tolerance and insulin resistance<sup>11–14</sup>. We recently described the 117 trends in prediabetes prevalence in the Mexican population<sup>7</sup>; we found that although lower 118 119 cut-offs of glycemic markers may be more adequate for screening strategies, they may not fully reflect the long-term health risk associated with prediabetes<sup>15</sup>. Notably, data on the 120 121 risk conferred by prediabetes for all-cause and cause-specific mortality in Mexico are 122 lacking. In this report, we aim to examine prediabetes as a risk factor for all-cause and 123 cause-specific mortality in Mexican adults previously enrolled in the Mexico City 124 Prospective Study (MCPS) and followed long-term for cause-specific mortality.

#### 125 **METHODS**

## 126 Study design and participants

Details on recruitment and follow-up of participants in MCPS have been described previously<sup>16</sup>. Briefly, participants living in two municipalities in Mexico City (Coyoacán and Iztapalapa) aged ≥35 years were invited to participate in the study between 1998 and 2004. The study was approved by Ethics Committees at the Mexican Ministry of Health, the Mexican National Council for Science and Technology, and the University of Oxford, UK. All participants provided written informed consent.

133 Data collection

Sociodemographic, health-related and lifestyle information were collected using an electronic questionnaire by trained nurses. All participants had their height, weight, hip circumference (HC), waist circumference (WC) and sitting blood pressure measured using calibrated instruments and standard protocols. A non-fasting venous blood sample was obtained and glycosylated hemoglobin (HbA<sub>1c</sub>) levels were measured using a validated high-performance liquid chromatography method<sup>17</sup> on HA-8180 analyzers with calibrators traceable to International Federation of Clinical Chemistry standards<sup>18</sup>.

141 Mortality follow-up

142 Participants were followed for cause-specific mortality through probabilistic linkage (based 143 on name, age, and sex) to the Mexican electronic death registry. Death registration in Mexico City is reliable and complete, with nearly all deaths medically certified<sup>19</sup>. Diseases 144 recorded on death certificates are coded using the International Statistical Classification of 145 146 Diseases and Related Health Problems, Tenth Revision, with subsequent review by study 147 clinicians (unaware of baseline information) to recode, where necessary, the underlying 148 cause of death. Participant deaths for the present study were tracked up to January 1<sup>st</sup>, 149 2021. We grouped deaths as cardiac (mainly ischemic heart disease), cerebrovascular,

other vascular (mainly peripheral arterial disease and thromboembolism), renal, acute diabetic crises (diabetic coma or ketoacidosis), hepatobiliary (mainly cirrhosis), other gastrointestinal (mainly peptic ulcer and gastrointestinal infections), neoplastic, respiratory (mainly pneumonia and chronic obstructive pulmonary disease), and external, ill-defined, or other causes of death. Full details on ICD-10 codes for individual causes of death are reported in **Supplementary Material**.

## 156 *Prediabetes and diabetes definitions*

Prediabetes was defined according to the HbA1c cut-offs recommended by the American 157 Diabetes Association (ADA) (HbA<sub>1c</sub> 5.7-6.4%)<sup>20</sup> and by the International Expert Committee 158 (IEC. HbA<sub>1</sub>c 6.0-6.4%).<sup>21</sup> We excluded individuals with previously diagnosed diabetes 159 160 (self-reported medical diagnosis or use of glucose-lowering pharmacotherapy), individuals 161 who reported regular use of glucose-lowering pharmacotherapy regardless of prior 162 diagnosis, and individuals with undiagnosed diabetes (HbA1c ≥6.5% in someone without a 163 prior diabetes diagnosis). To explore the mortality risks in the population with HbA1c levels 164 between the ADA and IEC cutoff points, additional analyses categorized participants according to HbA<sub>1</sub>c levels <5.7%, 5.7-5.9%, and 6.0-6.4%. 165

166 Statistical analysis

We limited our analysis to the population with prediabetes with complete data on HbA<sub>1</sub>c, mortality, and covariates. To limit the potential effects of reverse causation, we excluded those with self-reported chronic comorbidities at baseline (ischemic heart disease, stroke, chronic kidney disease, chronic obstructive pulmonary disease, cirrhosis, or cancer).<sup>22</sup> We evaluated the prevalence of ADA and IEC-defined prediabetes in the remaining participants separately by age (in 5-year groups) and sex. Uniformly age- and sexstandardized death rates were estimated for those with and without ADA and IEC-defined

prediabetes, as well as for the complementary HbA1c categories (above), and reported as
events per 1,000 person-years.

176 The primary analyses were restricted to deaths at ages 35-74 years (i.e., deaths one might 177 consider to be 'premature'), but some analyses of deaths at ages 75-84 were also performed. Cox proportional hazards regression was used to estimate mortality rate ratios 178 179 (RRs, estimated from the Cox hazard ratios) for all-cause and cause-specific mortality associated with prediabetes and HbA<sub>1c</sub> levels. Cox models yield cause-specific log hazard 180 181 ratios that provide a weighted average of the log mortality RRs in different time periods 182 which, irrespective of the proportional hazards assumption, provide useful summary 183 statistics of the average death RRs during the study. Participants who did not die from the 184 cause under study were censored at the earliest of: death from an alternative cause; the 185 end of the risk period under consideration (e.g., age 75 years for analyses of risk during ages 35-74 years); or the end of follow-up for mortality (January 1<sup>st</sup> 2021). 186

187 All models were stratified by sex and age at risk (in 5-year groups) using the Lexis expansion (*Epi* R package)<sup>23,24</sup> and were progressively adjusted for confounders in the 188 following order: 1) municipality of residence (Coyocán or Iztapalapa) (region-level 189 variations in population characteristics have been known to influence mortality related to 190 cardiometabolic diseases in Mexico<sup>25</sup>), and 2) education level (university/college, or other), 191 192 physical activity (none, regular), smoking (never, former, current), and alcohol consumption (never, former, current). Sensitivity analyses further adjusted for adjosity 193 markers (body mass index [BMI] and waist-to-height ratio [WHtR]). Subgroup analyses 194 estimated mortality RRs separately by age at risk and sex. The excess mortality 195 196 attributable to prediabetes (in a population without previously diagnosed or undiagnosed 197 diabetes) was estimated by applying the cause-specific mortality RRs to the number of

198 deaths among those with prediabetes. All analyses were conducted using R (version

199 4.2.1).

200 Role of Funding Sources

The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

203 **RESULTS** 

Of 159,517 participants who were originally recruited, 43,598 (27.3%) were excluded from the present analyses. These comprised 29,948 (18.8%) with diagnosed or undiagnosed diabetes at recruitment, a further 7,068 (4.4%) with missing data on HbA1c or covariates, or with uncertain mortality linkage, an additional 5,173 (3.2%) with chronic comorbidities at baseline, and1,409 (0.9%) aged  $\geq$ 85 years at recruitment (**Supplementary Figure 1**). Of the remaining 115,919 participants, 110,405 (95.2%) were aged 35–74 years and 5,514 (4.8%) were aged 75–84 years at recruitment.

211 Participant characteristics at baseline, stratified by HbA1c categories, are summarized in 212 Table 1. Participants in the highest HbA1c category (HbA1c 6.0%-6.4%) were older 213 (mean age 54 years), predominantly female (70.%), had higher BMI (mean 32 kg/m<sup>2</sup>), and 214 systolic blood pressure (mean 132 mmHg) and diastolic blood pressure (86 mmHg) than 215 participants with a lower HbA1c (HbA1c <5.9%). Participants in the higher HbA1c were 216 less likely to reside in Coyoacán (the more affluent of the two study districts) than 217 participants with a lower HbA1c (HbA1c <5.9%) (Table 1). Among the 110,405 participants aged 35-74 years at recruitment, 28,852 individuals (26%) had ADA-defined prediabetes 218 219 (HbA1c 5.7%-6.4%) and 7,203 (7%) had IEC-defined prediabetes (HbA1c 6.0%-6.4%). 220 The prevalence of prediabetes (regardless of definition) increased with age (at least up to 221 age 70) and was higher in women than men (at least after age 40) (Figure 1).

222 During a median of 18.6 (IQR 17.7-19.8) years' follow-up, there were 6,810 deaths at ages 35-74 years (including 1,742 from cardiovascular causes, 892 from renal causes and 108 223 224 from acute diabetic crises) and 7,067 deaths at ages 75-84 years. All-cause and cause-225 specific death rates (uniformly age- and sex-standardized) increased according to HbA1c 226 category, with the highest death rates being observed in participants with HbA1c 6.0-6.4% 227 (Figure 2A). Given that prediabetes prevalence markedly increased with age, we explored 228 the influence of baseline age and HbA1c categories. For participants aged <50 years at 229 recruitment, HbA1c 6.0%-6.4% was strongly associated with mortality risk, and this 230 association was preserved for participants aged 50-64 years at recruitment; however, we 231 identified that the graded increase in relative risk conferred by higher HbA1c levels was 232 lost in older participants (Figure 2B). When stratified by sex, we observed broadly similar death rate ratios in men and women (Supplementary Figure 2). Similar results were 233 234 obtained when examining deaths occurring at ages 75-84 years (Supplementary Figures 235 2 and 3).

236 After adjustment for age, sex and confounders, each one percent higher HbA1c was 237 associated with 11% higher risk of death from any cause at ages 35-74 years (RR 1.11 [95% CI 1.03-1.20]) (Supplementary Table 1, which also shows the RRs with more and 238 239 with less adjustment). Compared with individuals without prediabetes, those with ADA-240 defined prediabetes had 13% higher risk of death at ages 35-74 years (RR 1.13 [95% CI 241 1.07-1.19]) while those with IEC-defined prediabetes had 28% higher risk (RR 1.28 [95% 242 CI 1.18-1.39]) (Table 2). After further adjustment for adjosity these RRs were reduced to 243 1.06 (1.00-1.13) and 1.16 (1.05-1.27) respectively (Supplementary Table 1). Estimates were similar when including participants with other comorbidities at recruitment 244 245 (Supplementary Table 2).

246 Figure 3 and Table 2 show the distribution of the 6,810 deaths at ages 35-74 years in 247 participants with and without prediabetes (ADA and IEC definitions), as well as the cause-248 specific mortality RRs and their 95% CIs. Both ADA- and IEC-defined prediabetes were 249 significantly associated with increased risk of cardiac death, all cardiovascular death, renal death, and death from an acute diabetic crisis. In addition, ADA-defined prediabetes was 250 251 significantly associated with death from respiratory diseases. When examining deaths occurring at ages 75-84 years, cause-specific RRs tended to be slightly weaker, although 252 253 both ADA- and IEC-defined prediabetes remained strongly predictive of both renal death 254 and death from acute diabetic crises at these older ages (Supplementary Figure 4 and 255 Supplementary Table 3).

Overall, between 35 and 74 years of age in the population without previously diagnosed or undiagnosed diabetes, the excess mortality risk associated with ADA-defined prediabetes accounted for 4% of all deaths, including 6% of cardiovascular deaths, 10% of renal cause deaths, and 31% of deaths from an acute diabetic crisis (**Table 2**). By contrast, the excess mortality risk associated with IEC-defined prediabetes accounted for 2% of all deaths, including 3% of cardiovascular deaths, 5% of renal deaths and 14% of deaths from an acute diabetic crisis.

#### 263 **DISCUSSION**

In this large study of Mexican adults, we explored the association of HbA1c-defined prediabetes and all-cause and cause-specific mortality. Overall, both ADA- and IECdefined prediabetes were associated with an increased risk of all-cause mortality. The RRs associated with IEC-defined prediabetes (HbA1c 6%-6.4%) were somewhat larger than those associated with ADA-defined prediabetes (HbA1c 5.7%-6.4%). When considering cause-specific mortality, both definitions were associated with an increased risk of mortality from cardiovascular disease, kidney disease and acute diabetic crises, but only

the ADA definition was significantly associated with respiratory-related mortality, perhaps
reflecting increased statistical power for this definition. These results support the view that
prediabetes is a significant risk factor for cardiometabolic mortality.

A recently updated meta-analysis of prospective cohorts reported a 13% increase in the 274 risk of all-cause mortality when considering any definition of prediabetes<sup>3</sup>. When 275 276 examining definitions based on HbA1c, the IEC definition yielded a 21% increase in risk, while the ADA definition was not significantly associated with mortality<sup>3</sup>. In the present 277 study, we found that prediabetes was significantly associated with increased risk of 278 premature death from cardiovascular disease, kidney disease and acute diabetic crises 279 irrespective of the definition used. This is in line with previous reports from other 280 281 populations although, unlike previous reports, we did not find any significant association with cancer death.<sup>3,26-28</sup> Notably, estimates of mortality associated with ADA and IEC 282 definitions were reasonably consistent, with differences in attributable mortality being a 283 284 function of prevalence more than associated mortality risks. Expanding prediabetes 285 screening has been challenging given that preventive efforts should not only be aimed at predicting progression to type 2 diabetes, but also risk of all-cause and cause-specific 286 mortality<sup>2,3,20</sup>. Our findings support the view that the IEC definition of prediabetes could be 287 288 more useful at identifying individuals at the highest risk for cause-specific mortality 289 compared to the ADA definition, at the same time limiting potential adverse impacts on individuals and healthcare systems of labelling a large proportion of the population with a 290 diagnosis of prediabetes<sup>1</sup>. However, selecting the most optimal point for screening should 291 also balance the relevance of additional outcomes, perhaps most importantly type 2 292 293 diabetes.

The significance of prediabetes as a risk factor for all-cause and cause-specific mortality lies mainly within its high prevalence worldwide<sup>29</sup>. Previous efforts from our group reported

296 an increasing prevalence of HbA1c-defined prediabetes in Mexico between 2016 and 2022<sup>7</sup>. Notably, the predominantly urban MCPS sample in the current report yielded a high 297 298 prevalence of prediabetes (one quarter of those without diabetes had ADA-defined 299 prediabetes), similar to that estimated in a previous cross-sectional study of adults in Mexico City (26% of the adult population as a whole)<sup>30</sup>. In the present analysis, we 300 301 observed that among those without diabetes 6% of the premature cardiovascular deaths, 10% of the premature renal deaths and 31% of the premature acute diabetic deaths could 302 be attributed to the long-term hazards associated with ADA-defined prediabetes. 303 304 Interestingly, we also identified that the magnitude of the risk ratio of prediabetes for all-305 cause and cause-specific mortality decreased at older ages, being consistent with findings 306 from the ARIC study, which identified that regression to normoglycemia from prediabetes 307 was more common in this population, potentially contributing to the decrease in at-risk population over time $^{31}$ . 308

309 Our study has several strengths, including its large sample size, prospective design, and 310 prolonged follow-up, which allowed us to evaluate long-term prediabetes-related outcomes 311 compared with previous studies. However, we also acknowledge some limitations which should be considered to adequately frame our results. First, by only using HbA1c-based 312 313 definitions of prediabetes, we were unable to assess separately the mortality risks 314 associated with impaired fasting glucose and/or glucose intolerance; this may limit our ability to identify differential risk of adverse outcomes based on the specific definition 315 employed<sup>4,5,32</sup>. Nevertheless, by exploring both ADA and IEC HbA1c-based definitions we 316 317 contribute valuable insights to inform debate regarding the most appropriate definition of 318 prediabetes for predicting future cardiometabolic disease risks. Prediabetes has also been recognized to increase the risk of a cluster of multiple chronic comorbidities, which may 319 underlie the associations observed for mortality<sup>33</sup>. To isolate the effect of prediabetes, we 320

321 excluded individuals with comorbidities from our main analyses and focused on premature 322 death to reduce the potential influence of aging in our estimations. We expect that these 323 adjustments were more likely to generate results which were causal, but we cannot rule 324 out the possibility of residual confounding or reverse causality in our findings. Furthermore, 325 due to study design, we did not have prospective data to identify participants with 326 prediabetes who developed diabetes or other non-fatal events during follow-up; this prevented us from analyzing the relevance of prediabetes for mortality and 327 cardiometabolic risks independent of its association with increased risk to progression to 328 diabetes, an area which will require further evaluations with longitudinal assessments. 329 HbA1c levels have been known to be impacted over time by individual-level factors, 330 including chronic diseases, kidney, and liver function<sup>34</sup>; this effect may have been 331 mitigated by excluding individuals with comorbidities, but there remains a possibility of 332 unconsidered factors influencing HbA1c levels over time. Lastly, we acknowledge that 333 334 MCPS data primarily arises from two districts in Mexico City and our estimates may not be 335 representative of the whole Mexican population; however, large-scale prospective studies of non-representative cohorts of individuals such as MCPS can provide reliable evidence 336 about the associations of risk factors with disease that are widely generalizable<sup>35,36</sup>. 337

338 In this Mexican population prediabetes was significantly associated with increased risks of 339 cardiovascular, renal, and acute diabetic mortality. Given the increased risks associated with prediabetes, coupled with its high prevalence in Mexican adults, population-wide 340 screening strategies to facilitate its timely diagnosis, alongside implementation of 341 342 strategies to prevent and delay associated cardiometabolic diseases and related mortality, 343 should be considered. However, further work is needed to identify the appropriate outcome-driven definitions of prediabetes to promote efficient screening and prevention 344 strategies that minimize overdiagnosis and improve cardiometabolic outcomes. 345

346

347 **ACKNOWLEDGMENTS:** This project was registered and approved by the Research Committee at Instituto Nacional de Geriatría, project number DI-PI-006/2020. CAFM is 348 349 enrolled at the PECEM Program of the Faculty of Medicine at UNAM. CAFM and DRG are 350 supported by CONAHCYT. JAS was supported by Grant Number K23DK135798 from the NIH/NIDDK and by the Massachusetts General Hospital Executive Committee and Center 351 352 for Diversity and Inclusion Physician-Scientist Development Award. The authors thank the participants for their willingness to take part in this prospective study 20 years ago. This 353 research was conducted using Mexico City Prospective Study (MCPS) data obtained 354 355 through an open-access data request (application number 2022-012).

356 AUTHOR CONTRIBUTIONS: Establishing the cohort: PKM, JAD and RTC. Obtaining 357 funding: JBC, JRE, PKM, JAD, RTC and OYBC. Data acquisition, analysis, or 358 interpretation of data: CAFM, OYBC, CDPC, JPE, DRG, LFC, AVV, PSC, ANL, MRBA, JPDS, JBC, JRE, PKM, RTC, JAD, JAS, NEAV. Drafting first version of manuscript: 359 360 CAFM, OYBC. Critical revision of the report for important intellectual content: All authors. 361 All authors have seen and approved the final version and agreed to its publication. Each author contributed important intellectual content during manuscript drafting or revision and 362 accepts accountability for the overall work by ensuring that questions pertaining to the 363 364 accuracy or integrity of any portion of the work are appropriately investigated and resolved. 365 **DATA AVAILABILITY:** Data from the Mexico City Prospective Study are available to bona fide researchers. For more details, the study's Data and Sample Sharing policy may be 366 downloaded (in English or Spanish) from https://www.ctsu.ox.ac.uk/research/mcps. 367 Available study data can be examined in detail through the study's Data Showcase, 368 369 available at https://datashare.ndph.ox.ac.uk/mexico/. Code is available for reproducibility 370 of results at https://github.com/oyaxbell/prediabetes\_mcps/.

371 **CONFLICT OF INTEREST/FINANCIAL DISCLOSURE:** Nothing to disclose.

372 **FUNDING:** This research was also supported by Instituto Nacional de Geriatría in Mexico.

The MCPS has received funding from the Wellcome Trust (058299/Z/99), the Mexican Health Ministry, the National Council of Science and Technology for Mexico, Cancer Research UK, British Heart Foundation, and the UK Medical Research Council (MC\_UU\_00017/2). The funding sources had no role in the design, conduct or analysis of the study or the decision to submit the manuscript for publication.

- 378 **RIGHTS RETENTION STATEMENT:** For the purposes of open access, the
- authors have applied a Creative Commons Attribution (CC BY) licence to any
- 380 Author Accepted Manuscript version arising.

#### 381 **REFERENCES**

Blond MB, Færch K, Herder C, Ziegler D, Stehouwer CDA. The prediabetes
 conundrum: striking the balance between risk and resources. *Diabetologia*.
 2023;66(6):1016-1023. doi:10.1007/s00125-023-05890-y

Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and
 Management of Prediabetes: A Review. JAMA. 2023;329(14):1206-1216.
 doi:10.1001/jama.2023.4063

Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause
 mortality and cardiovascular disease: updated meta-analysis. *BMJ*. 2020;370:m2297.
 doi:10.1136/bmj.m2297

Wagner R, Heni M, Tabák AG, et al. Pathophysiology-based subphenotyping of
individuals at elevated risk for type 2 diabetes. *Nat Med.* 2021;27(1):49-57.
doi:10.1038/s41591-020-1116-9

394 5. Yacamán Méndez D, Zhou M, Trolle Lagerros Y, et al. Characterization of data395 driven clusters in diabetes-free adults and their utility for risk stratification of type 2
396 diabetes. *BMC Med.* 2022;20(1):356. doi:10.1186/s12916-022-02551-6

397 6. Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The 398 Epidemiological Evidence. *Annu Rev Public Health*. 2021;42:59-77. doi:10.1146/annurev-399 publhealth-090419-102644

Fermín-Martínez CA, Paz-Cabrera CD, Basile-Alvarez MR, et al. Prevalence of 400 7. prediabetes in Mexico: a retrospective analysis of nationally representative surveys 401 402 2016-2022. The Lancet Regional Health – Americas. spanning 2023;28. 403 doi:10.1016/j.lana.2023.100640

404 8. Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. 405 Epidemiology of diabetes mellitus in Mexico. *Nutr Rev.* 2017;75(suppl 1):4-12.

406 doi:10.1093/nutrit/nuw030

Almeda-Valdes P, Gómez Velasco DV, Arellano Campos O, et al. The SLC16A11
 risk haplotype is associated with decreased insulin action, higher transaminases and
 large-size adipocytes. *Eur J Endocrinol.* 2019;180(2):99-107. doi:10.1530/EJE-18-0677
 Williams AL, Jacobs SBR, Moreno-Macías H, et al. Sequence variants in

411 SLC16A11 are a common risk factor for type 2 diabetes in Mexico. *Nature*. 412 2014;506(7486):97-101. doi:10.1038/nature12828

413 11. Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, et al. METS-IR, a novel
414 score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2
415 diabetes. *Eur J Endocrinol.* 2018;178(5):533-544. doi:10.1530/EJE-17-0883

416 12. Bello-Chavolla OY, Vargas-Vázquez A, Antonio-Villa NE, et al. A High Incidence of

417 Metabolic Syndrome Traits in Mexicans Points at Obesity-Related Metabolic Dysfunction.

418 Diabetes Metab Syndr Obes. 2021;14:1073-1082. doi:10.2147/DMSO.S266568

Antonio-Villa NE, Bello-Chavolla OY, Vargas-Vázquez A, Mehta R, Aguilar-Salinas
CA, Metabolic Syndrome Study Group. The combination of insulin resistance and visceral
adipose tissue estimation improves the performance of metabolic syndrome as a predictor
of type 2 diabetes. *Diabet Med.* 2020;37(7):1192-1201. doi:10.1111/dme.14274

14. Rojas-Martínez R, Aguilar-Salinas CA, Romero-Martínez M, Castro-Porras L,
Gómez-Velasco D, Mehta R. Trends in the prevalence of metabolic syndrome and its
components in Mexican adults, 2006-2018. *Salud Publica Mex.* 2021;63(6, Nov-Dic):713-

426 724. doi:10.21149/12835

López-Jaramillo P, Nieto-Martínez RE, Aure-Fariñez G, et al. Identification and
management of prediabetes: results of the Latin America Strategic Prediabetes Meeting. *Rev Panam Salud Publica*. 2017;41:e172. doi:10.26633/RPSP.2017.172

430 16. Tapia-Conyer R, Kuri-Morales P, Alegre-Díaz J, et al. Cohort Profile: The Mexico

431 City Prospective Study. International Journal of Epidemiology. 2006;35(2):243-249.
432 doi:10.1093/ije/dyl042

433 17. Youngman LD, Clark S, Manley S, Peto R, Collins R. Reliable measurement of
434 glycated hemoglobin in frozen blood samples: implications for epidemiologic studies. *Clin*435 *Chem.* 2002;48(9):1627-1629.

18. International Federation of Clinical Chemistry (IFCC) Standardization of HbA1c.
NGSP. Accessed November 17, 2023. https://ngsp.org/docs/IFCCstd.pdf

438 19. Mikkelsen L, Phillips DE, AbouZahr C, et al. A global assessment of civil
439 registration and vital statistics systems: monitoring data quality and progress. *Lancet.*440 2015;386(10001):1395-1406. doi:10.1016/S0140-6736(15)60171-4

20. ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and Diagnosis of
Diabetes: Standards of Care in Diabetes—2023. *Diabetes Care*.
2022;46(Supplement 1):S19-S40. doi:10.2337/dc23-S002

Chatterton H, Younger T, Fischer A, Khunti K. Risk identification and interventions
to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. *BMJ*.
2012;345:e4624. doi:10.1136/bmj.e4624

Alegre-Díaz J, Herrington W, López-Cervantes M, et al. Diabetes and CauseSpecific Mortality in Mexico City. *N Engl J Med.* 2016;375(20):1961-1971.
doi:10.1056/NEJMoa1605368

23. Carstensen B, Plummer M, Laara E, Hills M. Epi: Statistical Analysis in
Epidemiology. Published online April 25, 2023. Accessed October 23, 2023. https://cran.rproject.org/web/packages/Epi/index.html

453 24. Plummer M, Carstensen B. Lexis □: An *R* Class for Epidemiological Studies with
454 Long-Term Follow-Up. *J Stat Soft*. 2011;38(5). doi:10.18637/jss.v038.i05

455 25. Bello-Chavolla OY, Antonio-Villa NE, Fermín-Martínez CA, et al. Diabetes-Related

456 Excess Mortality in Mexico: A Comparative Analysis of National Death Registries Between 457 2017–2019 and 2020. Diabetes Care. 2022;45(12):2957-2966. doi:10.2337/dc22-0616 Zhong GC, Ye MX, Cheng JH, Zhao Y, Gong JP. HbA1c and Risks of All-Cause 458 26. 459 and Cause-Specific Death in Subjects without Known Diabetes: A Dose-Response Meta-Analysis of Prospective Cohort Studies. Sci Rep. 2016;6:24071. doi:10.1038/srep24071 460 27. Islam Z, Akter S, Inoue Y, et al. Prediabetes, Diabetes, and the Risk of All-Cause 461 and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology 462 Collaboration on Occupational Health Study. Diabetes Care. 2021;44(3):757-764. 463 doi:10.2337/dc20-1213 464 Kowall B, Rathmann W, Heier M, et al. Categories of glucose tolerance and 465 28. 466 continuous glycemic measures and mortality. Eur J Epidemiol. 2011;26(8):637-645. 467 doi:10.1007/s10654-011-9609-v 29. Rooney MR, Fang M, Ogurtsova K, et al. Global Prevalence of Prediabetes. 468 469 Diabetes Care. 2023;46(7):1388-1394. doi:10.2337/dc22-2376 470 30. Barquera S, Hernández-Alcaraz C, Jáuregui A, et al. Diabetes Awareness, Treatment, and Control among Mexico City Residents. Diabetology. 2021;2(1):16-30. 471 472 doi:10.3390/diabetology2010002 473 31. Rooney MR, Rawlings AM, Pankow JS, et al. Risk of Progression to Diabetes Among Older Adults With Prediabetes. JAMA Internal Medicine. 2021;181(4):511-519. 474 doi:10.1001/jamainternmed.2020.8774 475 Lee CMY, Colagiuri S, Woodward M, et al. Comparing different definitions of 476 32. prediabetes with subsequent risk of diabetes: an individual participant data meta-analysis 477 478 involving 76 513 individuals and 8208 cases of incident diabetes. BMJ Open Diabetes Res 479 *Care*. 2019;7(1):e000794. doi:10.1136/bmjdrc-2019-000794 Schlesinger S, Neuenschwander M, Barbaresko J, et al. Prediabetes and risk of 480 33.

481 mortality, diabetes-related complications and comorbidities: umbrella review of meta482 analyses of prospective studies. *Diabetologia*. 2022;65(2):275-285. doi:10.1007/s00125483 021-05592-3

484 34. Guo W, Zhou Q, Jia Y, Xu J. Increased Levels of Glycated Hemoglobin A1c and
485 Iron Deficiency Anemia: A Review. *Med Sci Monit.* 2019;25:8371-8378.
486 doi:10.12659/MSM.916719

- 487 35. Chen Z, Emberson J, Collins R. Strategic Need for Large Prospective Studies in
- 488 Different Populations. *JAMA*. 2020;323(4):309-310. doi:10.1001/jama.2019.19736
- 489 36. Rothman KJ, Gallacher JEJ, Hatch EE. Why representativeness should be
- 490 avoided. Int J Epidemiol. 2013;42(4):1012-1014. doi:10.1093/ije/dys223

#### 492 FIGURE LEGENDS

# 493 Figure 1. Prevalence of ADA- and IEC-defined prediabetes in 115,919 MCPS participants

## 494 without previously diagnosed or undiagnosed diabetes, by age and sex

Dashed lines indicate overall prevalence of prediabetes for each definition stratified by sex.
ADA: American Diabetes Association. IEC: International Expert Committee. Analyses limited to
115,919 participants aged 35-84, and without previously diagnosed or undiagnosed diabetes (or
other chronic disease) at recruitment.

# Figure 2. All-cause and cause-specific mortality at ages 35 to 74 years associated with pre-diabetes

Analyses limited to 110,405 participants aged 35-74 and without previously diagnosed or 501 undiagnosed diabetes (or other chronic disease) at recruitment. (A) Uniformly age- and sex-502 503 standardized mortality rates per 1,000 person-years according to HbA1c categories, error bars 504 represent 95% confidence intervals. (B) Rate ratios with 95% confidence intervals for all-cause mortality associated with HbA1c categories, stratified by age at recruitment (<50 years, 50-64 505 years, or  $\geq$ 65 years). Labels represent the mortality rate ratio (bold) and number of events 506 507 (plain) for each category, the size of the squares is proportional to the amount of statistical 508 information. Models are stratified by sex and age at risk and adjusted for municipality, education 509 level, physical activity, smoking, and alcohol intake. Each 95% confidence interval reflects the 510 variance of the log risk in that 1 group.

## 511 Figure 3. Cause-specific mortality rate ratios at ages 35-74 years associated with ADA-

512 and IEC-defined prediabetes

ADA: American Diabetes Association. IEC: International Expert Committee. RR: Mortality rate ratio. CI: Confidence Interval. Analyses limited to 110,405 participants aged 35-74 and without previously diagnosed or undiagnosed diabetes (or other chronic disease) at recruitment. RRs are stratified by sex and age at risk and adjusted for municipality, education level, physical activity, smoking, and alcohol intake.

518 Figure 1



## 521 Figure 2



medRxiv preprint doi: https://doi.org/10.1101/2024.04.15.24305840; this version posted April 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 526 Figure 3

Cause of death	Prediabetes definition	No. deaths with/ without prediabetes		RR (95% CI)
Cardiac				
	ADA (≥5.7)	452/789	-8-	1.24 (1.10-1.41
	IEC (≥6.0)	148/1093	-0-	1.52 (1.28-1.82
Cerebrovascular				
	ADA (≥5.7)	138/257		1.08 (0.87-1.35
	IEC (≥6.0)	33/362		0.95 (0.66-1.36
Other vascular				
	ADA (≥5.7)	61/85		1.49 (1.05-2.13
	IEC (≥6.0)	24/122		2.10 (1.33-3.32
Renal				
	ADA (≥5.7)	150/245	-0-	1.35 (1.08-1.68
	IEC (≥6.0)	51/344		1.69 (1.24-2.31
Acute diabetic				
	ADA (≥5.7)	54/54		2.63 (1.76-3.94
	IEC (≥6.0)	22/86	0	3.43 (2.09-5.62
Gastrointestinal				
	ADA (≥5.7)	292/760	-8-	0.84 (0.73-0.97
	IEC (≥6.0)	109/943		1.34 (1.09-1.63
Neoplastic				
	ADA (≥5.7)	516/1063	-	1.09 (0.97-1.21
	IEC (≥6.0)	136/1443		1.09 (0.91-1.30
Respiratory				
	ADA (≥5.7)	368/701		1.24 (1.09-1.42
	IEC (≥6.0)	90/979		1.12 (0.89-1.39
ernal/III-defined/Other				
	ADA (≥5.7)	251/574		1.06 (0.91-1.25
	IEC (≥6.0)	65/760		1.07 (0.83-1.38
			0.50 1.0 2.0 4 RR for death at 35-74 years (with vs. without prediabetes)	1.0

medRxiv preprint doi: https://doi.org/10.1101/2024.04.15.24305840; this version posted April 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

## 528 Table 1. Baseline characteristics of 110,405 men and women aged 35-74 without previously diagnosed or undiagnosed

## 529 diabetes or other chronic disease at recruitment.

		HbA1c, %			
	All participants	<5.7	5.7-5.9	6.0-6.4	
	N = 110,405	N = 81,553	N = 21,649	N = 7,203	
Age (Years)	49 (10)	47 (10)	52 (11)	54 (10)	
HbA1c (%)	5.45 (0.37)	5.29 (0.26)	5.83 (0.10)	6.22 (0.12)	
Female sex (%)	74,768 (68%)	54,829 (67%)	14,872 (69%)	5,067 (70%)	
Residence in Coyoacán (%)	44,911 (41%)	37,050 (45%)	5,986 (28%)	1,875 (26%)	
University/college educated (%)	19,564 (18%)	16,400 (20%)	2,486 (11%)	678 (9.4%)	
Smoking (%)					
Never	53,106 (48%)	38,402 (47%)	10,910 (50%)	3,794 (53%)	
Former	19,969 (18%)	14,625 (18%)	4,033 (19%)	1,311 (18%)	
Current	37,330 (34%)	28,526 (35%)	6,706 (31%)	2,098 (29%)	
Alcohol intake (%)			· · · · · · · · · · · · · · · · · · ·		
Never	20,533 (19%)	14,633 (18%)	4,391 (20%)	1,509 (21%)	
Former	6,955 (6.3%)	5,281 (6.5%)	1,265 (5.8%)	409 (5.7%)	
Current	82,917 (75%)	61,639 (76%)	15,993 (74%)	5,285 (73%)	
Regular leisure-time physical activity (%)	25,273 (23%)	19,812 (24%)	4,193 (19%)	1,268 (18%)	
Body Mass Index (kg/m²)	29.0 (4.9)	28.3 (4.7)	30.5 (5.1)	32.0 (5.3)	
Waist-to-Height Ratio	0.60 (0.08)	0.59 (0.07)	0.63 (0.08)	0.66 (0.08)	
Waist-to-Hip Ratio	0.89 (0.08)	0.89 (0.07)	0.91 (0.07)	0.92 (0.07)	
Systolic Blood Pressure (mmHg)	126 (16)	125 (16)	129 (17)	132 (17)	
Diastolic Blood Pressure (mmHg)	83 (11)	82 (Ì1) <sup>′</sup>	84 (11)	86 (Ì1)	

## 539 Table 2: Excess cause-specific mortality at ages 35-74 years associated with ADA and IEC definitions of prediabetes at

#### 540 recruitment.

541

	ADA definition				IEC definition			
Course	No. deaths		Death RR*	Attributable	No. deaths		Death RR* (95%	Attributable
Cause	No	Prediabetes	(95% CI)	mortality	No	Prediabetes	CI)	mortality
	prediabetes			(%)	prediabetes			(%)
All causes	4,528	2,282	1.13 (1.07-1.19)	4	6,132	678	1.28 (1.18-1.39)	2
Cardiac	789	452	1 24 (1 10-1 41)	7	1 093	148	1 52 (1 28-1 82)	4
Cerebrovascular	257	138	1.08 (0.87-1.35)	3	362	33	0.95 (0.66-1.36)	0
Other vascular	85	61	1.49 (1.05-2.13)	14	122	24	2.10 (1.33-3.32)	9
All cardiovascular	1,131	651	1.22 (1.10-1.35)	6	1,577	205	1.42 (1.22-1.65)	3
Renal	245	150	1.35 (1.08-1.68)	10	344	51	1.69 (1.24-2.31)	5
Acute diabetic crisis	54	54	2.63 (1.76-3.94)	31	86	22	3.43 (2.09-5.62)	14
Gastrointestinal	760	292	0.84 (0.73-0.97)	-5	943	109	1.34 (1.09-1.63)	3
Neoplastic	1,063	516	1.09 (0.97-1.21)	3	1,443	136	1.09 (0.91-1.30)	1
Respiratory	701	368	1.24 (1.09-1.42)	7	979	90	1.12 (0.89-1.39)	1
External/ill- defined/other	574	251	1.06 (0.91-1.25)	2	760	65	1.07 (0.83-1.38)	1

#### 542

543 RR=Mortality Rate Ratio; CI=Confidence Interval; ADA definition= HbA1c 5.7-6.4%; IEC definition= HbA1c 6.0-6.4%\*Mortality rate

ratio estimates for those with vs without prediabetes at recruitment were stratified by sex and age at risk and adjusted for municipality,

545 education level, physical activity, smoking, and alcohol intake. Analyses excluded data from participants with previously diagnosed or

546 undiagnosed diabetes or other prior chronic disease. \*\*For each definition of prediabetes, the number of deaths attributable to the

547 excess risk associated with it was calculated as D x (RR - 1)/RR, where D is the proportion of deaths in the prediabetes group and

548 RR is the cause-specific mortality rate ratio for prediabetes versus no prediabetes.